Glenn Hanna, MD
Enriched profileDirector, Center for Salivary and Rare Head and Neck Cancers · Dana Farber Cancer Institute
Glenn Hanna is Director, Center for Salivary and Rare Head and Neck Cancers at Dana Farber Cancer Institute. OpenAlex indexes 556 publications with 7,715 citations (h-index 42); ClinicalTrials.gov lists 22 registered studies with this person as an investigator.
Data verified 23 Oct 2026
Overview
Updated 23 Oct 2026
Glenn Hanna, M.D., is Director, Center for Salivary and Rare Head and Neck Cancers at Dana Farber Cancer Institute. The public record shows 556 publications with 7,715 citations (h-index 42), centered on Head and Neck Cancer Studies, Cancer Immunotherapy and Biomarkers, Nonmelanoma Skin Cancer Studies. It also documents an investigator role on 22 registered clinical trials, industry payments reported by 9 companies.
- Most recent indexed publication: 2026 · Clinical cancer research
- Top research focus: Head and Neck Cancer Studies
- 22 registered trials on ClinicalTrials.gov
- Open Payments reporting from 9 companies
Generated from the cited public record · current as of 23 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 30 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 110.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 23 Oct 2026
Listed as an investigator on 22 registered studies on ClinicalTrials.gov. The most recent:
- Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0)
Sponsor: Dana-Farber Cancer Institute
- Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC
Sponsor: Dana-Farber Cancer Institute
- Toripalimab With Chemotherapy for Sinus Cancer
Sponsor: Glenn J. Hanna
Industry payments
Updated 23 Oct 2026
9 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year20257 payments
- Coherus Oncology, Inc.Program year20251 payment
- Merck Sharp & Dohme LLCProgram year20243 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Hormonal (systemic)
45.4%l-Thyroxine45.4%Levothyroxine Sodium100%Part D≥20 patientsSensory organs
16.5%Corticosteroid16.5%Dexamethasone100%Part D<11 patientsNervous system
14.4%Opioid Agonist14.4%Hydromorphone Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 23 Oct 2026
98 congress contributions (2012–2026) across AACR, ASCO, ASH, ASTRO, ESMO per OpenAlex. The most recent:
- A multicenter, randomized, double-blind, phase 2/3 study of ficerafusp alfa (BCA101) or placebo in combination with pembrolizumab for first-line treatment of HPV-negative, PD-L1–positive, recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): FORTIFI-HN01.
ASCO Annual Meeting
ASCO2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 23 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Enfortumab Vedotin plus Pembrolizumab as First-line Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Results from EV-202 Cohort 9.
Clinical cancer research
Clinical Trial2026 - A Longitudinal Comprehensive Biospecimen and Clinical Data Repository for Cancer Early Detection: The InAdvance Study.
Cancer epidemiology, biomarkers & prevention
Article2026 - Salvage of locoregionally recurrent head and neck cancer: an NRG oncology working group review.
Journal of the National Cancer Institute
Review2026 - Driving progress in recurrent and metastatic head and neck cancer: the NRG Oncology perspective.
Journal of the National Cancer Institute
Review2026
Most-cited works
by citation count (OpenAlex)- 01
- 02Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor SpheroidsArticle591 citations2017
- 03
- 04
- 05Response and Acquired Resistance to Everolimus in Anaplastic Thyroid CancerArticle321 citations2014
Network
Updated 23 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 23 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/glenn-hanna-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 23 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Editorial & leadership roles
journal and society appointments- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →tienda.elsevier.com ↗
Awards & honors
honors on the public record- Honoree
American Cancer Society 14th annual celebration (AstraZeneca Hope Lodge Boston commitment)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →bostonmagazine.com ↗
Secondary affiliations
appointments beyond the home institution- Harvard Medical School
associate professor of medicine
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Neal Futran, MD
University of Washington (UW Medicine)
Everett Vokes, MD
University of Chicago
Maura Gillison, MD
The University of Texas MD Anderson Cancer Center
Antonio Jimeno, MD
University of Colorado Cancer Center